Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.

Karen A. Kurdziel; William D. Figg; Jorge A. Carrasquillo; Susan Huebsch; Millie Whatley; David Sellers; Steven K. Libutti; James M. Pluda; William Dahut; Edward Reed; Stephen L. Bacharach

doi:10.1016/S1536-1632(03)00039-8

Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.

Karen A. Kurdziel^*, William D. Figg, Jorge A. Carrasquillo, Susan Huebsch, Millie Whatley, David Sellers, Steven K. Libutti, James M. Pluda, William Dahut, Edward Reed, Stephen L. Bacharach

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

PURPOSE: Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC. PROCEDURES: Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC. RESULTS: The percent change in PSA correlated with the FDG Delta%SUV(mean) (r=0.94, P<0.01) and Delta%metabolic tumor volume (r=0.91, P<0.01) but less well with Delta%blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032). CONCLUSIONS: PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.

Original language	English
Pages (from-to)	86-93
Number of pages	8
Journal	Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
Volume	5
Issue number	2
DOIs	https://doi.org/10.1016/S1536-1632(03)00039-8
State	Published - 2003
Externally published	Yes

Access to Document

10.1016/S1536-1632(03)00039-8

Cite this

Kurdziel, K. A., Figg, W. D., Carrasquillo, J. A., Huebsch, S., Whatley, M., Sellers, D., Libutti, S. K., Pluda, J. M., Dahut, W., Reed, E., & Bacharach, S. L. (2003). Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, 5(2), 86-93. https://doi.org/10.1016/S1536-1632(03)00039-8

@article{0dcd8dab06704c64b20a2df160c65f91,

title = "Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.",

abstract = "PURPOSE: Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC. PROCEDURES: Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC. RESULTS: The percent change in PSA correlated with the FDG Delta%SUV(mean) (r=0.94, P<0.01) and Delta%metabolic tumor volume (r=0.91, P<0.01) but less well with Delta%blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032). CONCLUSIONS: PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.",

author = "Kurdziel, {Karen A.} and Figg, {William D.} and Carrasquillo, {Jorge A.} and Susan Huebsch and Millie Whatley and David Sellers and Libutti, {Steven K.} and Pluda, {James M.} and William Dahut and Edward Reed and Bacharach, {Stephen L.}",

year = "2003",

doi = "10.1016/S1536-1632(03)00039-8",

language = "English",

volume = "5",

pages = "86--93",

journal = "Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging",

issn = "1536-1632",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "2",

}

Kurdziel, KA, Figg, WD, Carrasquillo, JA, Huebsch, S, Whatley, M, Sellers, D, Libutti, SK, Pluda, JM, Dahut, W, Reed, E & Bacharach, SL 2003, 'Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.', Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, vol. 5, no. 2, pp. 86-93. https://doi.org/10.1016/S1536-1632(03)00039-8

Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. / Kurdziel, Karen A.; Figg, William D.; Carrasquillo, Jorge A. et al.
In: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, Vol. 5, No. 2, 2003, p. 86-93.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.

AU - Kurdziel, Karen A.

AU - Figg, William D.

AU - Carrasquillo, Jorge A.

AU - Huebsch, Susan

AU - Whatley, Millie

AU - Sellers, David

AU - Libutti, Steven K.

AU - Pluda, James M.

AU - Dahut, William

AU - Reed, Edward

AU - Bacharach, Stephen L.

PY - 2003

Y1 - 2003

N2 - PURPOSE: Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC. PROCEDURES: Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC. RESULTS: The percent change in PSA correlated with the FDG Delta%SUV(mean) (r=0.94, P<0.01) and Delta%metabolic tumor volume (r=0.91, P<0.01) but less well with Delta%blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032). CONCLUSIONS: PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.

AB - PURPOSE: Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC. PROCEDURES: Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC. RESULTS: The percent change in PSA correlated with the FDG Delta%SUV(mean) (r=0.94, P<0.01) and Delta%metabolic tumor volume (r=0.91, P<0.01) but less well with Delta%blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032). CONCLUSIONS: PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.

UR - http://www.scopus.com/inward/record.url?scp=5444229812&partnerID=8YFLogxK

U2 - 10.1016/S1536-1632(03)00039-8

DO - 10.1016/S1536-1632(03)00039-8

M3 - Article

C2 - 14499149

AN - SCOPUS:5444229812

SN - 1536-1632

VL - 5

SP - 86

EP - 93

JO - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging

JF - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging

IS - 2

ER -

Kurdziel KA, Figg WD, Carrasquillo JA, Huebsch S, Whatley M, Sellers D et al. Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 2003;5(2):86-93. doi: 10.1016/S1536-1632(03)00039-8

Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.

Abstract

Access to Document

Fingerprint

Cite this